Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris revisits his November 2024 forecasts to assess how they’ve held up through mid-2025, giving them an overall grade of A-. He examines which trends played out as expected, where the landscape shifted more dramatically, and how these developments are reshaping patient access strategies. To learn more, register for ConnectiveRx’s free webinar on September 24: Building Resilient Patient Support W...
